Our Kymab pipeline powers discovery of novel therapeutics and development and validation of vaccine candidates.
Our capacity in infectious disease has been primed by investment from Bill & Melinda Gates Foundation and partnerships with leading academic groups that give Kymab a unique position to develop, in partnership, the best-in-class, humanised B-cell repertoire mouse for vaccine development and assessment as a pre-clinical model.
We are addressing the increased need for effective prevention, control and treatment of chronic and emerging infectious diseases in both the developing and developed world. The Kymouse™, with a human antibody repertoire, provides an experimentally accessible surrogate for assessing normal human immune responses, identifying therapeutic antibodies and determining vaccine efficacy in pre-clinical models of infection.
In our Infectious Disease and Vaccine therapeutic area we use the power of the immune system to fight infections, exploring opportunities in:
- the use of vaccination to prevent infection;
- treatment with therapeutic antibodies to remove or reduce infection;
- targeting host cell functions to alter the balance of the immune system to prevent pathogenesis of acute infections or remove persistent infections.
Currently we have active programmes in four infectious diseases: malaria, Salmonella Typhi, HIV and Bordetella pertussis.
By using the Kymouse™ platform, immunisations with whole viable, whole-attenuated, whole-killed or subunit immunogens of a pathogen simultaneously yield a vaccine efficacy development process and a therapeutic antibody discovery process.
In our internal projects and partnerships, we immunise Kymouse™ with selected immunogens to:
- identify antigens and epitopes that confer protection through using defined monoclonal antibodies in infection challenge and pathogenesis models;
- identify human monoclonal antibodies that confer broadly cross-protective responses to antigenically diverse pathogens;
- define cross-protective epitopes and re-engineer and test ‘smart vaccines’ iteratively;
- use the broadly cross-protective monoclonal antibodies to treat or prevent infection whilst vaccine candidates are developed;
- prove immunisation efficacy, immunisation regimen strategy and vaccine standards for vaccine immune response;
- discover B-cell repertoire sequence-based correlates of protection for clinical trials.